Meningococcal Disease Treatment Market, By Therapy Type (Antibiotics (Penicillin, Ampicillin, Chloramphenicol, and Ceftriaxone) and (Vaccines (Bivalent, Trivalent, and Tetravalent)), By Route of Administration (Injectable and Oral), By Distribution channel (Hospital Pharmacy, Retail Pharmacy, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Feb 2022

Code : CMI4913

Pages :151

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Meningococcal Disease Treatment Market Restraint

High cost of meningococcal vaccination and low coverage of the same are expected to hinder the growth of the global meningococcal vaccines market

Moreover, meningococcal vaccination is optional in several countries, which is also expected to limit the market growth.

High cost of meningococcal vaccination

Restaints

Global Meningococcal Disease Treatment Market– Impact of Coronavirus (Covid-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in more than 114 million infected individuals worldwide as of March 2^nd 2021.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Furthermore, players operating in the global meningococcal disease treatment market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing of product due to irregularities in transportation facility. Moreover, distributors are experiencing irregular demand for products from the retailers due to increasing number of patients suffering from COVID-19 and other life threatening disorders.